STEVEN CURLEY to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications STEVEN CURLEY has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.529
-
Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomedicine. 2014 Aug; 10(6):1121-30.
Score: 0.218
-
Luciferase-based protein denaturation assay for quantification of radiofrequency field-induced targeted hyperthermia: developing an intracellular thermometer. Int J Hyperthermia. 2012; 28(3):202-9.
Score: 0.047
-
Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res. 2010 Dec 01; 16(23):5712-21.
Score: 0.043
-
Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer. 2010 Jul 01; 116(13):3285-93.
Score: 0.042
-
Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery. 2010 Aug; 148(2):319-24.
Score: 0.042
-
Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol. 2008; 7(4):313-26.
Score: 0.035
-
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012 Dec 20; 30(36):4566-72.
Score: 0.012
-
Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347.
Score: 0.011
-
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
Score: 0.011
-
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6.
Score: 0.011
-
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010 Nov; 17(11):2870-6.
Score: 0.011
-
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009 Dec 02; 302(21):2338-44.
Score: 0.010
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.009
-
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008 Nov 10; 26(32):5254-60.
Score: 0.009
-
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007 Dec 15; 110(12):2761-7.
Score: 0.009
-
Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005 Aug 01; 23(22):4853-5.
Score: 0.007